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S228 Oral Presentationsfrom 48 states. Autologous and allogeneic HCT recipients were
equally likely to enroll (P 5 .59) and view pages (P 5 .74). Across
all races, non-white survivors were less likely to enroll compared
to whites (P\.001), but once enrolled viewed as many pages (P 5
.18). 14% were computer use beginners, 52% were intermediate
users, and 34% were experts; these groups did not differ in pages
viewed (P 5 .89). Survivors from rural versus urban areas were
equally likely to participate (P 5 .45) and utilize the site (P 5 .14).
Once randomized to site access, 70% logged on at least once. The
median number of pages visited was 7 (range 0-179). Participants
$40 years old were more likely to login at least once compared
with those\40 (P 5 .004) but age groups did not differ in pages
viewed (P5 .15). Females weremore likely to visit the site thanmales
(77% vs. 65%, P5 .007) as well as to viewmore pages (M5 21.3, SD
5 28.0 vs. M5 11.7, SD5 18.3, P\.001). Similarly, transplant sur-
vivors\10 years were more likely to enroll in the study than $10
year survivors (P\.001) but did not view more pages (P 5 .26).
Discussion: The internet provides access to long-term HCT survi-
vors.While online approaches reach a broad population and are well
utilized, additional strategies are needed for males and younger than
40 years old HCT survivors to engage them in the online resources.
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In 2009, mutations in the gene for dedicator of cytokinesis 8
(DOCK8) have been identified as the cause of the autosomal recessive
variant of Hyper-IgE syndrome. The clinical presentation of this
primary combined immunodeficiency is characterized by eczema, de-
bilitating viral infections of the skin, chronicmucocutaneous candidi-
asis, pulmonary infections, severe allergies, vascular complications
and a high risk for malignancy, mostly lymphoma or skin cancer.
While the long-term prognosis of affected patients is not yet
clearly defined, the high morbidity and mortality of this disease sug-
gest HSCT as a potential curative measure. On behalf of the EBMT
inborn errors working party we retrospectively studied the outcome
of HSCT in patients with DOCK8 mutations.
A total of fifteen patients from 10 institutions were identified, 4 of
whom had been previously reported. Three patients had malignant
disease. At a median age of 13 years (3-18) transplantation from
aMUD (n5 9), MFD (n5 2) or MSD (n5 4) was carried out. Con-
ditioning was fully myeloablative in 4, of reduced intensity in 10 or
minimal in 1. After amedian follow-up of 8months (2-89) the overall
survival is 80% (12/15). Only one patient had grade III or greater
acute GVHD; he later developed extensive chronic GVHD and
died from infection. Two other patients died, one from sepsis, the
other from progression of pre-existing lymphoma. T-cell chimerism
at last follow-up was.99% in 12/14 and 50-90% in 2/14. Of the 12
surviving patients 9 of 9 who were evaluable had complete correction
of their immunodeficiency. Other symptoms such as eczema (disap-
peared in 11/12, improved in 1/12), allergies (5/7; 2/7), mollusca (6/
8; 2/8), bacterial infections (6/6; 0/6), fungal infections (7/7; 0/7) and
pulmonary function deficits (4/4; 0/4) responded very well. One pa-
tient developed a thyroid carcinoma 7 years post transplant, likely
because of a TBI-containing conditioning regimen.Longer follow-up will be needed to ascertain that HSCT will
correct themalignancy risk, as theDOCK8molecule has been impli-
cated as a tumor suppressor and is expressed in extra-hematopoietic
tissues. A survey to define the natural course of disease and to guide
treatment recommendations for all patients is currently underway on
behalf of ESID and EBMT. In summary, HSCT corrects the immu-
nodeficiency and other disease manifestations in DOCK8 deficiency
and this treatment should be offered at least to all patients with
severe disease manifestations.
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Infantile malignant osteopetrosis (IMO) is due to a heterogeneous
group of mutations resulting in abnormal osteoclast function; more
than half of the IMO cases have mutations in the TCIRG1 gene. Al-
logeneic hematopoietic cell transplantation (HCT) is currently the
only curative therapy for IMO. We report here our experience in
IMO at King Faisal Specialist Hospital & Research Center
(KFSHRC).
Patients andMethods: Between January 1993 andDecember 2008,
25 children with IMO underwent HCT at KFSHRC, median time
from diagnosis to HCT was 3.7 month (range, 1-66 months), and
median age atHCTwas 6months, (range, 2-75months), ten patients
(40%) had severe hematopoietic deficiency, and severe visual impair-
ment at HCT. Donor source was fully matched siblings in 23 pa-
tients and partially matched unrelated cord blood in 2 patients. All
patients were conditioned with busulfan (BU) and cyclophospha-
mide (CY).
Results:Nine mutations were detected in TCIRG1, seven of which
were novel. One novel mutation was detected in CLCN7 gene.
Seven patients had no mutation detected in TCIRG1, CLCN7 or
OSTM genes. Engraftment occurred in 23 patients (92 %). Acute
GVHD and veno-occlusive disease occurred in 6 and 4 patients, re-
spectively. Seven patients (28%) had secondary graft failure at a me-
dian of 6 months post HCT (range, 3-14 months). Sixteen (64%)
patients remain alive. Chimerism studies at the last contact are avail-
able for 14 patients, and all but 2 patients have stable mixed chime-
rism. At median follow-up of 9.8 years (95% CI: 5.4-14.2 years)
ranging from 3.6 to 15.2 years, the overall survival (OS) and event-
free survival (EFS) are 55%, and 52%, respectively. All surviving pa-
tients had evidence of osteoclast function at the last evaluation, and
none of them had any further vision deterioration.
Conclusion: Children with IMO have favorable survival after allo-
geneic HCT. Although engraftment is probably not significantly af-
fected by the age, we recommend that early HCT be done to
preserve vision and final height as much as possible. Due to the small
number of patients, and the fact that a good percentage of our cases
had no mutations in the known genes, we were not able to relate
a specific genotype with outcome. However, TCIRG1 appears to
be an important gene in IMO in Saudi patients, similar to other pop-
ulations. Larger series are required to demonstrate a genotype–phe-
notype, and genotype-outcome correlation.
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Bierings, M.B.1, Wolfs, T.1, Tessa, V.2, Jaap, B.J.1, Imke, B.2 1UMC
Utrecht, Utrecht, Netherlands; 2UMC Utrecht, Utrecht, Netherlands
Background: Invasive fungal infections are of great concern in pedi-
atric HSCT recipients. Voriconazole is an important drug both for
prophylaxis as well as for therapy. Optimum trough levels are be-
tween 1-5 mg/l. It is unclear whether these levels are reached with
current pediatric dosing schedules. We retrospectively analysed
the use of voriconazole in our unit between 2007 and 2011.
Use of voriconazole: 92 children between 0-19 years of age under-
went HSCT. 57 of them (64%) were treated with voriconazole. 21%
of them were\2 yrs, 47% 2-12-yrs and 32 % .12 yrs.
Oral Presentations S229Voriconazole was given as prophylaxis in 44% of cases, 23% re-
ceived it empirically and 33% as therapy. 14 of the 19 children
treated therapeutically had aspergillosis (11 possible, 2 probable, 1
proven). Dosing was according to the summary of product character-
istics. For children\2 yrs the recommended dosage for 2-12 yrs was
used. Voriconazole was prescribed for a mean period of 63 days
(range 6-415). In 11% of cases the drug was stopped due to toxicity.
Therapeutic drug monitoring of voriconazole: An adequate
trough level was defined as 1-5 mg/ml. First measurement of trough
levels was after a median of 5 days.
Only in 8% of children\2 years an adequate level was reached at
initial dosing.
3 of 15 children between 2-7 yrs of age on recommended dosage
had adequate levels at initial dosing (20%); in children aged 7-12
yrs 83% had adequate initial levels if dosage was as recommended.
14/33 patients.2 yrs on recommended dose had voriconazole levels
below the limit of detection (\0.5 mg/ml). 9% of all patients had an
initial trough level . 5 mg/ml.
The mean dose (range) to reach adequate trough levels for chil-
dren\2 was: 365 mg oral (220-600) and 29.4 mg/kg i.v. (5.2-70).
For the age group 2-7 years adequate levels were reached with
a mean dose of 26.2 mg/kg i.v. (20.7-29.6). .12 years this was
17.6 mg/kg i.v. (11.9-19.6).
Intrapatient variability of levels on constant dosage was 0.7-3.5
fold.
Conclusion: We conclude that therapeutic drug monitoring is in-
dispensable for correct dosage of voriconazole. Dosage recommen-
dations for children need adjustment, especially in the \2 age
group. Intra patient variability is also a major concern and necesit-
tates continued level measurements. Patient characteristics that de-
termine pharmacokinetic variability need to be identified in future
studies.
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FLUDARABINE + EXPOSURE-TARGETED BUSULFAN IN CHILDREN WITH
MALIGNANT AND NON-MALIGNANT DISEASES: AN EFFECTIVE AND LOW
TOXIC REGIMEN
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Background: Busulfan (Bu) as myeloablative agent is used in condi-
tioning regimens prior to HSCT. We recently found a clear associ-
ation between Bu-exposure and outcomes. Comparison studies in
adults showed a favorable toxicity profile for fludarabine+busulfan
(FludBu) compared to the conventional BuCy regimen.We recently
initiated a prospective study analysing the effectively of FluBu inmy-
eloid malignancies and all non-malignant indications in pediatrics.
We compared the outcomes with our Bu(-exposure targeted)/Cy/
(Mel) from a previous cohort (2005-2008).
Methods: Fludarabine 40mg/m2 was given in 1 hour prior to a 3
hour infusion of once daily busulfan. The target area under the curve
(AUC) for Bu was 75-95 mg*h/L (in total) in both groups. Bu dose
targeting, based on therapeutic drug monitoring was performed be-
fore the second dose. Primary endpoint was event free survival (EFS)
and survival. Secondary endpoints were acute graft-versus-host dis-
ease (aGvHD), neutropenic period and the number of erythrocytes
and thrombocytes transfusions. A risk factor analysis was performed
using univariable and multivariable COX regression.
Results: 100 patients were included: 65 unrelated-CBT, 22 a MSD
and 13 a MUD. 52 patients were included in the FludBu group (me-
dian follow up 244 days; range 22-769) and 48 in the BuCy(Mel)
group (1015 days; range 6-2085). The median exposure of busulfan
was 88 (81-94)mg*h/L inFluBu and82 (74-100)mg*h/L inBuCy(Mel).
The groups were comparable regarding age, cell source, gender, in-
dication for BMT and match-grade. The probability on EFS in
FludBu and BuCy(Mel) was 74+/-6% and. 70+/-7% (NS), resp.
No difference in aGvHD ($grade 2: 20 vs.28%) was found. A trend
to a lower ‘‘non-relapse mortality’’ was found in the FluBu group
7+/-4% vs. 19+/-6% (p 5 0.08). The period of neutropenia was
median 11 in the FludBu compared to 20.5 in BuCy(Mel) (HR
0.38, p 5 0.05, CI95% 0.20-0.75). The median number of erythro-
cytes transfusion was 1 (range 1-13) in the FludBu group and 5 (0-22)
in the BuCy(Mel) group (p 5 0.02) and thrombocyte transfusions
4 (range 0-33) vs 10 (range 2-44; p 5 0,02). Less VOD was seen in
BuFlu 3% vs. 22% (p 5 0.01).Conclusion: Bu with a total target AUC of 75-95mg*h/l in combi-
nation with Flud showed to be an effective and low toxic regimen in
comparison to BuCy(Mel). A shorter neutropenic period and a lower
number of transfusions were needed in FludBu. FludBu as reduced
toxicity regimen showed promising results.72
UNRELATED BONE MARROW TRANSPLANTATION (UBMT) FOR CHIL-
DREN AND ADOLESCENTS WITH FANCONI ANEMIA (FA) USING CYCLO-
PHOPHAMIDE, FLUDARABINE AND RABBIT ATG: ANALYSIS OF 33
PATIENTS TRANSPLANTED AT A SINGLE INSTITUTION
Bonfim, C., Ribeiro, L., Loth, G., Bitencourt, M., Kanaan, S.N.,
Koliski, A., Funke, V., Pilonetto, D., Zanis-Neto, J., Pasquini, R. Federal
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FA is a rare disease characterized by progressive bonemarrow fail-
ure, congenital anomalies and a striking predisposition to cancer.
HSCT is the only treatment able to cure the hematological compli-
cations related to this disease. In the absence of a fully matched re-
lated donor, the use of an unrelated donor is recommended but is
still associated with an increased rate of rejection and GVHD. Ob-
jective: Analyze the outcome of 33 pts with FA submitted to an
UBMT using CY+FLU+rATG in the conditioning regimen.
Patients and Methods: Period: 02/02 - 02/11, Age 5-18s (M:
10years) Sex: 17F/16M; Preparatory regimen: CY60mg/kg +
FLU125mg/m2 + rATG 4-6mg/kg; GVHD prophylaxis: Cyclo-
sporine and methotrexate. Stem cell source: bone marrow. All pts
and donors were HLA typed at least for low-resolution class I (locus
A, B, C) and high resolutionDRB1. 29pts were fully compatible (8/8)
and 4pts had one or two mismatches.
Results: 26 pts are alive between 8 months and 8ys days after BMT
(M: 2,7ys) with an overall survival (OS) of 79% in 3 years. 32 pts sur-
vived more than 28 days and were evaluated for engraftment. 3 pts
had only neutrophilic engraftment and all died between days +30
and +117 post BMT. One pt had primary graft failure (mismatch
in locus C) and received a 2nd UBMT (alive and well 4.8 ys after
UBMT). No late rejection occurred in this group of pts. Early com-
plications: mucositis grade III -IV: 75%. Moderate to severe arterial
hypertension: 70%. No pt developed severe hepatic sinusoidal syn-
drome. Hemorrhagic cystitis:7pts. Acute GVHD grade II-IV oc-
curred in 12/31 evaluable pts while chronic GVHD occurred in
11/26 evaluable pts (limited: 6pts; extensive: 5pts). Seven pts died be-
tween 20-117 days post UBMT (M: 50 days). Cumulative incidence
of TRM at 100 days was 18%. Causes of death were generally related
to infection (bacterial or fungal) or GVHD complications. Pts under
10 years had an excellent survival (94%) as well as those with fully
compatible donors (86%).
Conclusions:The results fromUBMT in FA have improved consid-
erably during the past few years. In this study, pts under the age of 10
had an excellent survival, equal to the one observed in pts with fully
matched related donors. Early referral, the use of conditioning reg-
imen containing fludarabine and the possibility of finding well
matched unrelated donors (65% of them found in the Brazilian reg-
istry) may have contributed for the success of this protocol.73
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PATIENTS
WITH WISKOTT ALDRICH SYNDROME (WAS): ANALYSIS OF 36 CHIL-
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WAS is a rare X-linked disease characterized by recurrent infec-
tions, eczema, thrombocytopeniawith small platelets andan increased
predisposition to autoimmunity and lymphoid malignancies. HSCT
is the only treatment with the possibility of cure.
Objective: Retrospective analysis of 36pts with WAS submitted to
HSCT at a single institution.
Patients andMethods: 36 boys; age: 0.9-14 ys (M: 2 ys), period: 04/
1992 05/2011. The majority of pts had severe manifestations of the
